Psychedelics Investing

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? Legislators in seven U.S. states are introducing psychedelics bills as they seek to emulate measures that have been approved in Oregon and Colorado.  From state-regulated psychedelic therapy...

What a year for psychedelics! It feels like we’ve come a long way since the sector explode in 2019-2020, the launch of Benzinga's Psyched, companies’ massive migration from private to public, MAPS’ initiation of Phase 3 MDMA trials, the surge of the psilocybin wave,...

Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries The agency regulating all things related to psychedelic-assisted therapy (PAT), Health Canada released a notice to stakeholders on risk-management measures for clinical trials, a...

Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Currently, in the form of a pill, the compound was conceived by Vancouver, BC-based natural drug development company Filament Health (OTC:...

Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million). The company issued more than 7.7 million common shares at a unit price of $0.09 (CA$0.12) for gross proceeds of $680.458 (CA$930,...

Mydecine Innovations Group Inc. (OTC: MYCOF), a biotech company engineering next-gen psychedelic therapeutics, announced that it has closed the sale of all of issued and outstanding shares of its wholly-owned subsidiary, Mindleap Health Inc. to PanGenomic Health Inc., a precision health...

Psychedelics biotech firm Clearmind Medicine Inc. (OTC: CMNDF) (NASDAQ: CMND) has announced the pricing of its underwritten public offering of 1,153,847 common shares at a public price of $6.50 per share, for aggregate gross proceeds of $7.5 million, to close on or about November 17, 2022. ...

Crypto Billionaire Brock Pierce Joins Psychedelic Venture Fund, Says 'Potential Reward Is Immeasurable' Benzinga was the first to report that Brock Pierce, the crypto billionaire, economist and philanthropist serving as chairman of the Bitcoin Foundation, has joined Jeremy Gardner’s...

(Part four of a four-part series) See previous stories in this series:  Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo's Investment Fundamentals & Specificities  Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Public Market Valuations &...

(Part three of a four-part series) See previous stories in this series:  Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo's Investment Fundamentals & Specificities  Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Public Market Valuations...

(Part two of a four-part series) See the previous story in this series: EXCLUSIVE Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo's Investment Fundamentals & Specificities    The Palo Santo venture fund invests in private companies. As such,...

(Part one of a four-part series) Daniel Goldberg and Tim Schlidt are co-founders and partners behind Palo Santo, one of the most remarkable VC funds investing in psychedelics today. The company recently closed a capital round of $50 million for investment in a diverse portfolio...

Cathie Wood’s ARK Genomic Revolution EFT has been making big investments in the psychedelics sector since February 2022, most notably in Atai Life Sciences (NASDAQ: ATAI). The fund has now gone deeper and released an extensive report exploring “the therapeutic merits”...

This article was originally published on Microdose and appears here with permission.  In response to a worldwide mental illness epidemic and flood of capital from investing firms, the psychedelic industry has seen explosive growth in recent years. The newfound enthusiasm is advancing rapidly...

A key player in the biotech-meets-psychedelics space, HAVN Life Sciences Inc. (OTC: HAVLF) announced it will complete a consolidation of its issued and outstanding common shares ‎on the basis of one (1) post-consolidation common share for every thirty (30) pre-consolidation common shares...